leukemia

[Annals of Hematology] Scientists investigated the effect of ZEN-3365, a novel BRD4 inhibitor, on acute myeloid leukemia cells in regard to the Hedgehog pathway.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master iPSC line.

[Journal of Clinical Oncology] In this single-center, Phase I trial, researchers administered anti-CD7 chimeric antigen receptor (CAR) T cells, manufactured from either previous stem-cell transplantation donors or new donors, to patients with relapsed or refractory T-cell acute lymphoblastic leukemia, in single infusions at doses of 5 × 105 or 1 × 106 cells per kilogram of body weight.

[Cancer Immunology Research] Investigators found that although NK cells did not express endogenous TYRO3 on the cell surface, activated NK cells rapidly acquired TYRO3 from tumor cells via trogocytosis in vitro and in vivo.

[Cancer Research] In vitro treatment of Idh2R140Q/NHD13 thymocytes with enasidenib, a selective inhibitor of mutant IDH2, led to a marked decrease in leukemic cell proliferation, demonstrating that Idh2R140Q/NHD13 mice could serve as a useful in vivo model for the study of early/immature T cell precursor acute lymphoid leukemia (ALL) development and therapy.

[Blood] The authors analyzed 4708 adult acute myeloid leukemia patients recruited into Study Alliance Leukemia trials to investigate the prognostic impact of CEBPAsm.